International Journal of Pharmacy and Herbal Technology

e-ISSN: 2583-8962 Vol. 3, Issue 1 (January – April, 2025) pp: (3653-3673)

A Review on: Current Trend in Drug Discovery

Rupali N. Shingare *, Savita D. Sonwane, Sanjay K. Bais

Fabtech College of Pharmacy, Sangola, Solapur, Maharashtra, India

*Corresponding Author: shingarerupali956@gmail.com

Received Date: January 15,2025; Published Date:18, March,2025

Abstract

Many sophisticated methods have been developed, revolutionizing the process of discovering new drug. In order to determine a prospective "target" that may be affected by a medicine and is Subsequently "validated" as being implicated in the disease, pharmaceutical researchers Undertake molecular level assembly. In order to assemble the Root causes of illness of disease. In order to change the condition, Next the researchers look for a "lead Compound "that can take action against their target. One of the most important aspects of a modern Drug development program is collaboration between academics and industry. Highlighting The most recent developments and trends in the primary goal of this piece. The drug development process is made better by a number of cutting-edge methods and Contemporary research fields like proteomics, metabolomics, chemo genomics, and Genomics, among others.

Keywords – Target, Receptor, Drug Discovery, QSAR, clinical studies, preclinical Studies,new drug application.

INTRODUCTION

The nineteenth century saw the beginning of regarding the process of discovery with the proposal among the hypothesis of responsive compounds by John Langley in 1905. The first logical development of synthetic pharmaceuticals was done in 1910 by Sacachiro Hata (the creator of Salvarsan) and the father of modern chemotherapy, Paul Ehrlich who created structure-activity relationship of arsphenamine salvarsan connection from the atoxyl employed in in syphilis, Trypanosomiasis, or sleeping disease. In 1908, Ehrlich received Nobel Prize.QSAR, or quantitative structure–activity relationship, is a concept that was first presented by Hansch & Fujita in 1960. Following that, in 1970, the technique advanced as a result of the application of combinatorial chemistry and molecular modeling. [1] To maintain their brand and financial standing, the pharmaceutical sector works tirelessly to comprehend illnesses and develop safe, effective medications. The main issues facing the pharmaceutical sector today are low productivity, patent expiration, growing R&D expenses, and narrowing pipelines.[2] Current developments in proteomics, metabolomics, chemogenomics, genomics, and computational approaches reduce costs and lengthen turnaround times for higher-quality drug discovery and development. distinct methodologies are commonly used in drug discovery and development. Both structure-based and target-based approaches to drug discovery.[3] Target-based strategies identify potential therapeutic targets initially; in structure-based approaches, compounds that exhibit desired pharmacological activity are further developed and optimized. The target-based strategy's primary motivator for the past ten years has been the genomics revolution. Verifying whether a particular target contributes to the illness or not is essential for target validation. Figure outlining the typical procedures for finding a novel medication to treat a particular illness.



***Figure 1*:** *Drug Discovery and Development Approach*

The two primary divisions into which the process of discovering new medications falls are drug development and drug discovery. The process of finding and developing a chemical compound to interact with a disease target after it has been identified and validated is known as drug discovery. [4] Drug development entails meeting all prerequisites that must be fulfilled before a novel chemical is approved for initial testing in humans. Preclinical and clinical trials enable drug testing. At present, each molecular entity incurs research and development costs of about US $1.8 billion.[5] Numerous studies have attempted to quantify the cost; the US Pharmaceutical Manufacturers Association (PhRMA) has provided the most frequently cited statistics, which are based on research conducted at the Tufts Center in Boston by DiMasi and others.[6],[7]

History of drug discovery process

The history of drug creation and discovery begins with among utilization of natural compounds for medical reasons in antiquity. Significant advancements were made in the 19th century with the discovery of substances like quinine and morphine. The 20th century witnessed the emergence of synthetic chemistry, which resulted in the creation of significant medications and antibiotics like penicillin. The discipline underwent significant transformation with the emergence of biopharmaceuticals in the late 20th century, which included monoclonal antibodies. Drug discovery now entails intricate procedures that include cutting-edge technology like genetics and bioinformatics, as well as high-throughput screening and personalized therapy.[8]



***Figure 2*:** *Drug Molecule*

Some notable drugs and their discoveries include

Morphine

Isolated from the opium poppy in 1804, morphine is a potent pain killer.

Quinine

Isolated from Cinchona bark in 1820, quinine was the first antimalarial agent.

Colchicine

Isolated from Colchicum autumnale in 1820, colchicine was used to treat joint pain and gout.

Aspirin

The first widely used medication, aspirin was isolated from the chloral hydrate: the first synthetic medicine, discovered in 1869 and still in use in some nations today.

Taxol

This drug was initially derived straight from the Pacific yew bark but a semisynthetic process was later developed to make it. [9]

Several classifications of drug discovery and development

Small Molecule Drug Discovery

Focuses on identifying low molecular weight compounds that can modulate biological processes.

Biologics Development

Involves the discovery and development of large molecules, such as proteins, monoclonal antibodies, and vaccines.

Natural Products

Utilizes compounds derived from natural sources (plants, fungi, bacteria) as potential therapeutics.

High-Throughput Screening

Employs automated processes to test large libraries of compounds for biological activity.

Designing drug reasonably

Involves creating novel medications-based designing on the knowledge among biological targets and their structures.

Combination Therapy

Focuses on developing treatments that use multiple drugs to enhance efficacy and reduce resistance.[10]

Objectives of drug discovery

The purpose of drug discovery is to find molecules that are able to treat diseases by interacting with parti molecular targets within body. The drug discovery process involves several objectives, including:

Identifying a target

Research is conducted to identify a target that can be inhibited or activated to treat a disease.

Finding a drug-like compound

A search is conducted to find a small molecule or biological therapeutic that can be used as a drug.

Screening compounds

Compounds are screened to determine which ones are likely to be developed into drugs.

Cross-screening

Compounds are screened to see if they interfere with other related targets.

Improving lead compounds

Enhance the lead molecule by utilizing structure–activity relationships (SARs).

Advantages of drug discovery

Treating illnesses

New medications can provide superior alternatives to current treatments or treat illnesses or disorders that cannot be treated with other medications.

Less side effects

Compared to current therapies, new medications may have less side effects.

Greater therapeutic efficacy

New medications may outperform current therapies in terms of therapeutic efficacy.

Better amenability

Compared to current therapies, new medications may be more agreeable.

Fewer drug–drug interactions

Compared to current treatments, new medications may have fewer drug–drug interactions.

Cost-efficiency

Time can be cut and cost-efficiency can be raised with the aid of high-throughput screening.

Faster medication development

Machine learning has the capacity to speed up the drug development process.

Economic value

New medications with significant potential for profit can be found with the aid of machine learning.

Patient safety

By monitoring adverse events and other safety concerns, pharmacovigilance works to guarantee that medications are safe for use by patients.

Disadvantages of drug discovery

Drug discovery can be a Wide-ranging, the time-consuming procedure and complicated work with a number of drawbacks, such as:

Time

Drug development programs only produce licensed pharmaceuticals in 4% of cases, and it can take ten to fifteen years to get a drug to market.

Cost

Hundreds of millions of dollars may be needed for the comprehensive testing and trials.

Uncertainty

There is a lot of doubt surrounding the possibility that a treatment will be successful.

Animal models

Human medication reactions are frequently not reliably predicted by animal models.

Human capacity

The quantity of data that can be analyzed at any one time by human researchers is restricted.

Absence of biomarkers

To objectively identify and quantify biological states, there are insufficiently reliable diagnostic and therapeutic biomarkers.

Regulatory procedures

It can be difficult to understand the current regulatory procedures.[11]

Application of drug discovery

Taking care of illnesses

Drug development aids in the treatment of diseases or illnesses for which there is no other known cure.

Enhancing Current Medical Interventions

By increasing their effectiveness, lowering their negative effects, or minimizing drug interactions, current medicines can be made better with the aid of drug discovery.

Using AI

Large-scale data analysis can be made more accurate and efficient with the use of artificial intelligence (AI) techniques like machine learning and natural language processing. AI can help predict a drug candidate's toxicity and effectiveness.

Gene Therapy

Introduction of healthy genes to replace or repair damaged genes [12].

Stem Cell Therapy

Replacing or repairing damaged tissues with stem cells.

Nanotechnology

Development of nanoparticle-based drug delivery systems. [13]

Machine Learning (ML)

Use of ML algorithms to predict drug efficacy and toxicity. [14]

Current challenge in drug discovery

Lack of understanding: The pathophysiology of many diseases, particularly those affecting the neurological system, is not well understood.

Animal modelling

Animal models don't always precisely anticipate how humans will respond to medications. This may result in the inaccurate classification of medication candidates as either safe or harmful to people.

Patient populations

Since every person's disease develops differently, certain people may respond better to a particular treatment than another.

Time and cost

With an average cost of $2 billion and a time to market of 10 to 15 years, drug development is an expensive and time-consuming procedure.

Compound safety

For challenging targets, improving compound safety is getting harder.

Pipeline challenges

The term "development pipeline" refers to the procedure used to introduce a new medication to the market. In the pipeline drug discovery. a disease target is first identified, validated, and then a chemical molecule that selectively interacts with the target is developed. A successful medicine takes an average of US$1.8 billion over 10 to 15 years to develop. It is series of stages that a new drug goes through from research and development to market:

Inadequate Collaboration Among Academia, Industry, and Government.

Success rate

Just 20% of medications that proceed through in-human studies are approved, and just 0.1% of medications that start pre-clinical trials are able to be tested on humans.

Preclinical models

The preclinical stage is costly and time-consuming, and traditionally uses in vivo animal models.

Clearance prediction

Predicting clearance (CL) is a challenge, especially when complex processes like drug transporters are involved. [15]

Stages of Drug discovery and development

Drug discovery and development stages: There are multiple steps in the drug discovery and development process, including

Drug Discovery

Identification of the target

Validation of the target

Identification of Leads

Optimization of leads

Drug Development

Preclinical research

New drug application

The Clinical research

Approval



Figure 3*: *Stages of Drug Discovery

Drug discovery

Target identification

Targets are particular, naturally occurring elements of cellular or molecular structures that are implicated in illness and cause disease; examples of these include receptors, enzymes, nucleic acids, hormones, and ion channels. The pharmacist chooses his target based on the disease that he is most interested in. More than 600 genes encoding GPCR have been found, and G-protein coupled receptors (GPCR) are the main families now under investigation. GPCRs are implicated in over thirty diseases in humans, such as diabetes insipidus, hypo- and hyperthyroidism, retinitis pigmentosa, several reproductive problems, and even carcinoma.[16] Targets such as ion channels, hormones, transport proteins, nucleic acids, and enzymes may be accountable for a given ailment. Novel targets are identified through the use of modern technologies such as phenotype screening, data mining in silico, in vivo methods utilizing genetic engineering, somatic mutagenesis using RNAi technologies, metabolic pathways (metabolomics), glycosylation of proteins (glycosilomics), gene expression profiling (proteomics), and phenotype screening. The main method used for target identification is through CRISPR.

Characteristics of Target identification

The biomolecule(s) that the drug targets are usually proteins, which can exist in complex or Isolated form.

The unique places on biomolecules complement one another.

When a biomolecule attaches to a tiny molecule, its structure may alter, although these changes are often reversible.

Different physiological reactions that result from the biomolecule's structural change cause the status of the cell, organ, tissue, or body to be regulated.

The physiological reactions brought on by modifications in the structure of biomolecules are important for complicated control and can treat diseased diseases.

Over the course of the pathogenic process, the biomolecule's expression, activity, and structure may alter.

Drugs are small chemicals that bind to biomolecules.[17]

Target validation

In order to validate a target, it must be shown that a molecular target is essential to the progression of a disease, and changing the target is probably going to have a therapeutic impact.[18]



Figure 4*: *Target Identification and Validation

Basically, there are six possible steps in the target validation process:

Finding a promising biomolecule.

Assessing its suitability as a target.

Creating a biological activity measurement bioassay.

Building a screen with a high throughput.

Running a screening to locate hits.

Assessing the strikes.

Finding targets in biology that are thought to be linked to a specific disease or illness, or the mounting evidence supporting such a connection. The initial phase of the drug research process There are several sources of information that support these targets' involvement in the modulation of illness. [19]

Hit to identification and validation

The next logical step is to ascertain whether the small molecule leads behave as planned against the specified targets. This is known as identification and validation. Hits can be found using a variety of techniques, including high-throughput screening, knowledge-based approaches, and virtual screening. After the initial screening, hits must be validated, and there are a few options once more. [20]

Moving from hit to lead

The goal now is aim to maximize every hit series to generate Being more picky molecules after multiple hit series have been produced. It is advisable to work on several series at once because it is possible that some popular series will not succeed, frequently because of unique series traits. By concentrating on several structurally distinct collections of popular shows, this probability will be lessened.[21]

Lead optimization

At this stage, the objective is to resolve any potential structural flaws in lead compounds while maintaining the desirable characteristics in order to produce a preclinical treatment candidate. This stage can be used to find out if the medication metabolizes in the right area of the body or if there are any side effects that need your immediate attention.

For this process, an integrated strategy is recommended. Together, specialists in medicinal chemistry, drug metabolism, computational chemistry, and other disciplines can offer unique perspectives on this last stage of the procedure.

Late lead optimization

A crucial step before beginning preclinical and clinical research is late-stage optimization, which assesses a lead molecule's additional pharmacological safety.Eliminating the most hazardous leads, locating and advancing the leads with the best overall safety profile, and creating a well-defined translational risk and hazard profile to support further in vitro testing are the goals. [22]



Figure 5*: *Lead Optimization

Methods

In silica Method

Modern terminology like "in-vivo" and "in vitro" refer to biological testing conducted in a laboratory setting; the word "in-silico" alludes to research conducted by a computer. There is little consensus over the origins of the phrase "in-silico," with multiple researchers claiming to have played a part of Silica Method. In the field of drug development, computational chemists now play a mainstream role rather than a supporting one. Computational techniques Similar to molecular docking, virtual screening (VS) and pharmacophore-based virtual screening can be applied when the atomic coordinates of the target protein and a library of drug-like substances are available. By sorting through enormous virtual libraries, these in silico techniques shorten the lead-discovery time. Determining the binding affinity between the ligand and the receptor is a step in the molecular docking process. The process known as "receptor-based docking" ranks and scores each chemical from the chemical database based on its binding affinity by using the three-dimensional structure of the receptor. "Ligand based docking" employs techniques like 3D form matching, substructure searching, similarity searching etc. Depending on the data dimensions, different QSAR, such as 1D to 6D QSAR, are used. The quantity of hydrogen bond donors or acceptors, the molecular weight, and the number of rotatable bonds and other chemical descriptors are frequently employed for SAR correlation. Pharmacophore mapping is the process of creating a three-dimensional pharmacophore, which is a collection of molecular elements necessary for biological activity and interaction with a specific receptor. These elements include aromatic rings, hydrophobic regions, both positively and the negatively charged groups, hydrogen bond donors and acceptors, furthermore their relative spatial orientation. The possibility of related activity can then be determined by searching a chemical library for members who fit these molecular characteristics.

The application of this data to the development of computer models or simulations that can be used to predict results, put forth hypotheses, and ultimately result in breakthroughs or improvements in medicine and therapy. [23]

Objectives of in silica Method

Predicting therapeutic potential

Saving time and resources

Identifying potential drug candidates

Improving drug

Candidates



Figure 6*: *In Silico Method of Drug Discovery

Advantages of in silica Method

Here are numerous benefits of using in silico approaches in drug discovery, such as:

Cost-effective

Compared to animal research, in silico techniques are more affordable.

Time-saving

Drug development can be completed faster and with fewer resources when using in silico approaches.

Safer: The design of pharmaceuticals can be aided by in silico approaches.

Predictive

The therapeutic potential of novel medications can be anticipated using in silico techniques.

Versatile

In silico techniques are applicable to a wide range of tasks, such as regulatory drug safety review, drug development, and environmental agent toxicity prediction.

Non-harmful

Neither humans nor animals are at risk from in silico technologies.

Machine learning

By controlling uncertainty in drug discovery data, machine learning models can enhance in silico procedures.

Data access

Large amounts of data can be accessed with the aid of in silico technologies.

Figure 7*: *In Silico Method Testing

Disadvantages of in silica Method

Verification and precision to guarantee accuracy and reliability, in silico forecasts must be verified with experimental data

Biosystems' complexity Because biological systems are so complex, simulating their behavior in silico can be challenging.

Acceptance by regulators Regulatory bodies will not embrace in silico methodologies for drug development decision-making until they have received substantial evidence of their reliability and usefulness.

Data accessibility and caliber It might be challenging to gather complete, high-quality data, which is important for model creation and validation.

Sequences of proteins Although there is an increasing amount of protein sequences available, there is still a discrepancy between the quantity of sequences and their crystal structures. Ideal alignment of structures Only tiny proteins can have their optimal structural alignment computed.

Application of in silica Method

Identify potential drugs

Large compound databases can be screened using in silico techniques to find possible therapeutic candidates.

Optimize drug structure

The safety, effectiveness, and binding affinity of possible medication candidates can all be enhanced by in silico methods.

Predict drug properties

In silico techniques can forecast a medication's absorption, distribution, and the way a drug candidate will attach to a target protein. Potential drug candidates' binding affinity, safety, and effectiveness as well as their toxicity, metabolism, and excretion characteristics can all be enhanced using in silico techniques

Design compounds

In silico methods can design compounds based on the chemical structure of Well-known ligands that bind to the target protein.

Predict toxicity

In silico methods can help predict a drug's toxicity in the early phases of drug development.

Optimize processes

In silico methods can help optimize processes during drug development.

In silico methods can save time and money during drug discovery, but they cannot completely replace in vitro and in vivo procedures. [24]

Some examples of in silico methods include:

Virtual screening

Target-based methods

Similarity searching

Pharmacological compounds

Homology modeling

Quantitative structure-activity connection

Machine learnings

Information mining

High throughput synthesis technique

With the help of combinatorial chemistry, medicinal chemists can quickly and in a variety of ways put together a sizable library of molecules. DOS, or diversity-oriented synthesis. [25]. Solid supports and -tagging technologies have frequently been used with success in classic library synthesis methods like split pool and parallel synthesis. In order to address the difficulties posed by reactant. [26] Is comparable to combinatorial chemistry, however variety is introduced in a different order. Diversification in combinatorial libraries is accomplished" y modifying the limbs of a shared core scaffold. On the other hand, in DOS, the library covers greater chemical space since it contains identical appendages on several core scaffolds. In a process called as biology-oriented synthesis (BIOS) [27] chemical libraries are created using iterations resembling scaffolds of recognized biological functions, frequently natural products. Solid supports and phase-tagging technologies have been successfully used in many instances in conventional library synthesis methods, including split-pool and parallel synthesis. Liquid-phase organic synthesis (LPOS) which uses.[28]



***Figure 8*:** *High Throughput Techniques*

Here are some key features of HTS

Speed

HTS can screen up to 10,000 compounds per day.

Automation

HTS uses robotics, liquid handlers, and software to test compounds.

Cost-effectiveness
HTS can quickly screen large compound libraries.
Target specificity
HTS focuses on a single mechanism to identify target-specific compounds.
Miniaturization
HTS often uses miniaturized cell-based assays.
Toxicity assessment
HTS can assess a compound's toxicity.
Objective of HTS
Identify active compounds.
Provide data for prediction.
Streamline workflows.
Improving data collection Speed.
Clarifying properties
Advantages
Efficiency
HTS is faster and more efficient than traditional synthesis techniques.
Automation
To test substances, HTS employs robotics, liquid handlers, and software.
Data sets
HTS can generate large data sets, which can provide more comprehensive insights.
Applications
HTS has applications in many areas, including drug discovery, organic synthesis, and the development of solar cells, batteries, and superconductors.
Reduced human error
Automated systems use barcodes to identify and manage plates, which reduces human error.
Safe disposal
Automated systems can safely dispose of test plates after screening runs.
Disadvantages
Cost
HTS can be expensive, requiring the purchase of machines, assay reagents, microplates, pipette tips, and more. Screening a large compound library can cost over $300,000.
Errors
Both false positives and false negatives can result from HTS. False negatives occur when actual active chemicals are not detected, whereas false positives are compounds that are detected as hits but are not active.
Knowledge base
HTS requires a broad knowledge base that spans multiple disciplines, such as chemistry, biology, and medicinal chemistry.
Technical challenges
HTS can be technically challenging and requires a good understanding of the equipment.
Multiwall plates
HTS systems are based on multiwall plates, which can be time-consuming and labour-intensive to operate. They also consume a lot of reagents.
Complex drug combinations
It can be difficult to screen for complex drug combinations.

Automated data analysis

Automated data analysis may not capture important aspects of protein behaviour.

Applications of HTS

Medication discovery in the pharmaceutical business, high-throughput screening (HTS) is a widely used technique to find compounds having pharmacological or biological activity.

HTS is frequently carried out in micro titer plates and has the capacity to screen up to 10,000 compounds daily. Development and research of materials High-throughput synthesis techniques can be used to study a wider range of reaction conditions and ingredients, which can lead to new discoveries in materials like polymeric and composite materials.

Storing energy Battery materials can be screened using high-throughput synthesis techniques for characteristics including phase stability, ionic diffusivity, and capacity.

Solar panels Solar cells are composed of numerous layers of thin films, and their composition and production processes can be investigated using high-throughput synthesis techniques.

LEDs (light-emitting diodes) can be produced using high-throughput synthesis methods.[29]

Some examples of HTS including;

Solar cells

Batteries

Light emitting diode

Superconductors

Drug Development

Following the drug discovery phase is the drug development process. Potential drug candidates are investigated in two stages: preclinical pharmacology, which includes studies on animals, and clinical pharmacology, which involves investigations on humans.

Figure 9*: *Drug Development Process

Preclinical studies

Preclinical studies are carried out in a lab setting using animal models, Preclinical studies. A medication's potential to seriously injure humans must be determined by researchers prior to trying it on humans. Rats, mice, pigs and canines used. [30]

There are two types of preclinical studies;

In vitro studies

In vitro these studies are carried out in a lab setting away from the animals.

In vivo studies

These tests are carried out inside the living animals.[31]

Key fields of study include

Studies on the toxicity profile of acute, sub-acute, and chronic conditions.

A drug's therapeutic index, which measures its safety and efficacy progression, is determined by dividing its median effective dosage (ED50) by its median lethal dose (LD50).
ADME investigations, which stand for absorption, distribution, metabolism, and elimination.[32]



Figure 10*: *Various Types of Animals Used in Preclinical Studies

Preclinical studies are crucial in drug discovery as they assess
Safety,
Efficacy,
Pharmacokinetics before human trials,
Helping to minimize risks and optimize treatment potential.

Investigational New Drugs Application

This are made once preclinical research demonstrate efficacy. The item (goods) is then sent for the clinical research investigation. if the INDA filing is approved.
The primary IND kinds;
Investigating IND
An Emergency IND
Therapy for IND

Investigating IND

An Investigator IND is submitted by a physician who oversees the administration or distribution of the experimental medication, performs the study, and directs the investigation. A physician may submit an IND for study in order to propose examining an approved product or an unapproved drug for a new use or in a patient population that has not yet been diagnosed.

An Emergency IND

Using It in an Emergency In an emergency, when there is insufficient time to file an IND in accordance with 21 CFR, Sec. 312.23 or Sec. 312.20, an IND allows the FDA to authorize the use of' an investigational medication. It is also used if there isn't an approved study protocol or if a patient doesn't meet the protocols' standards.

Therapy for IND

Treatment INDs are filed for investigational drugs that show promise in clinical trials for severe or immediately life-threatening conditions while the FDA evaluation and final clinical work are being completed.

Clinical research

The goals of these studies are to ascertain the drug's pharmacologic and metabolic effects in humans, the adverse reactions that increase using dosage, and, if feasible, to obtain preliminary data on efficacy. Approximately 90% of medication candidates that were enrolled in clinical trials ended up failing. The primary causes of failure in 1991 were toxicity (12%), ineffectiveness (30%), and PK/bioavailability issues (40%). The primary causes of failure in 2000 were toxicity (20%), commercial and market factors (21%), and ineffectiveness (27%) Twenty. Clinical studies are divided into four stages:[33]

Following are various phases of clinical trials

Phase I

Phase II

Phase III

Phase IV



Figure 11*: *Various Phases of Clinical Research

Phase I (initially in Humans)

Trail

Patients

20–100 volunteers in good health who volunteer in a single location.

Subjects receive no benefit.

Study period

Brief, ranging from a few days to many weeks or months.

This study is an example of an open-label (no comparator or placebo) un managed single- or multiple- dose study.[34]

Purpose

The goal is to conduct PK/PD and mechanism of action (ADME) research. The

Impact of pharmacology.

Consistency, adverse reactions, and toxicity at varying concentrations.

Promising initial results.

Determine the most Likely range of dosages and most likely possible toxicities while evaluating safety.

Seventy percent of drugs advance to the next phase.[35]

Figure12*: *Clinical Trials Phases

Phases II: (Therapeutic Exploratory)

Patients: 100 – 300 patients will be the focus of the condition.

Research duration: from a few months to two years.

Research purpose: efficacy and side effects.

Trial type: randomized, double-blinded, parallel, placebo- or active-controlled, one or more-dose, multiple centers.[36]

Purpose

Dose range determination (the lowest and maximum doses that are in effect).

The drug's efficacy in treating the intended ailment or disease; the Maximum Tolerated Dose (MTD).

The frequency of in brief-term adverse reaction and associated hazards. * The drugs percentage that advance to phase 33 is determined by pharmacokinetics.[37]

Phases III (therapeutic confirmatory)

Patients Between 1000 and 3,000 individuals with the specific illness or condition.

Study period: one to four years.

Study Design: Multicentre, parallel, double-blinded, randomized, placebo or active control.

Purpose

Efficiency (High level). Equilibrium risk/benefit ratio.

Information on long-term security, including typical adverse reaction, pharmacological interactions, and variations in age, rate, and gender.

Illustrates dosage Evaluation of security and effectiveness.

Drugs That Go on to following stage: 25–30% of Them.

Once the phase III trials are finished, the application is submitted to the relevant regulatory organizations in order to obtain clearance.

The product is introduced to the market for marketing purposes following the regulatory authorities' requisite approval. [38]

Phase IV :(Post-Marketing Therapeutic Use)

Individuals: The disease/condition is present in many 100 - 1000 of individuals.

Study Design: Multicenter, Randomized, Placebo or Active Control

Purpose

Carry out pharmaco -economic trials and Quality of Life Trails (QOL) trials.

Does the medication work better than other therapies on the market?

Gathering long-term safety data; doing epidemiological research on safety. conducting extra surveillance in case of unanticipated or uncommon negative effects. The pharmaceutical Phase 0 studies are carried out by the industry to identify drug candidates with the best human pharmacokinetic properties.[39]

Approval

The drug discovery and approval process are a multi-step procedure that can take many years and cost millions of dollars. The process includes;[40]



Figure 13*: *Drug Approval Process in Drug Discovery

Recent techniques

Artificial biology to ensure comprehend interactions between gene and protein and create pre-trial pharmacological models, researchers can synthesize cells.

Machine learning Advanced CRISPR tumor models can be analyzed by machine learning to target cancer cells. Computational techniques Rapid screening of a sizable compound library to identify possible binders is made possible by computational techniques.

Monoclonal antibodies A greater surface area of the target molecule can be interacted with by monoclonal antibodies, improving target discrimination across closely related targets.
Synthetic intelligence in order to recommend treatment plans, artificial intelligence (AI) can evaluate a patient's medical records and compare them with a database.
Nanotechnology Drugs based on nanotechnology that can be used to treat, diagnose, or prevent a variety of illnesses are known as nanomedicines.
3D-bioprinting Improved medication models can be made with 3D bioprinting.
In the specialized computer-aided drug design (CADD), drug-receptor interactions are simulated through computational techniques. CADD techniques rely significantly on databases, software, and technologies related to bioinformatics. As a result, there is a lot of overlap between bioinformatics and CADD study. In terms of CADD research, bioinformatics has a number of important topics.[41]

Recent trends in drug discovery

A computer plays a crucial part in the development of novel compounds in the hunt for more effective therapeutic agents in pharmaceutical, medical, and other scientific research. Rational medication design and structure combined in biology; new medicinal drugs are discovered. An innovative method of identifying new leads, in-silico drug design (CADD) is a quickly expanding field that supports drug discovery and development research. The proliferation of bioinformatics, cheminformatics, genomics, proteomics, and structural data has yielded hundreds of new targets and ligands with benefits like reduced costs, quicker time to market, better understanding of drug-receptor interactions, and accelerated drug discovery and development, among others.

In pharmaceutical, medical, and other scientific research, a computer is an essential tool, particularly when creating new compounds to identify more potent therapeutic agents. Structural biology and logical drug design are combined to create new therapeutic medications. Two The creative process of finding novel leads in the quickly developing field of in-silico drug designing, or CADD, aids drug discovery and development research. The proliferation of bioinformatics, cheminformatics, genomics, proteomics, and structural data has enabled hundreds of newer targets and ligands with advantages like cost savings, time-to-market, comprehensive understanding of drug-receptor interactions, and accelerated drug discovery and development.

Different approaches of CADD, including as Drug design based on structure and ligands, are employed as promising strategies based on their respective needs. These two techniques can be used in conjunction with molecular docking and virtual screening to identify and optimize lead compounds.

Large quantities of chemical compounds can be synthesized, purified, analysed, and screened using combinatorial chemistry more quickly and affordably than using conventional synthesis techniques. Combinatorial chemistry can be used in a lab to synthesis many compounds. It able to also be used to construct combinatorial libraries using a variety of database tools, including as SmiLib, GLARE, Chem T, CLEVER, Library Synthesizer, etc.
Various CADD techniques or conventional hit-identifying methods, such HTS tests, can be used to find ligands, which include inhibitors, activators, agonists, antagonists, and substrate analogues. HTS and CADD approaches are generally viewed as complimentary to each other due to their different strengths and weaknesses for drug development.
When it comes to identifying new hits, the pharmaceutical industry uses two main approaches for screening compounds: virtual screening and high-throughput screening, which involves chemical manufacturing in addition to screening against assays based on proteins or cells.[42]

CONCLUSION

Since the 1990s, advances in molecular biology, biotechnology, genomics, and bioinformatics have brought about a revolution in the drug discovery process the process among finding new medication is still expansive time-consuming, inefficient, and has a low number of novel treatment discoveries despite all the advancements. "The most fundamental and lasting objective of synthesis is not production of new compounds, but production of properties," as stated by sharp less and colleagues. Thus, the creation of novel compounds with the necessary biological properties need not be the exclusive objective of medicinal chemists. In order to generate the appropriate products for the right patients, the correct research and technology may be applied in the correct way in the appropriate moment.

REFERENCES

1. J.N. Langley, The Reaction of Cells and Nerve-Endings to Certain Poisons, Chiefly as Regards the Reaction of Striated Muscle Nicotine and Curari, Journal of Physiology,1905: 33(4):374-413.
2. J. Smith, L. Brown, Challenges in the Pharmaceutical Sector Addressing Low Productivity Patent Expiration and Growing Research and Development Costs, Journal of Pharmaceutical Sciences and Research, 2021:45(3):456-465.
3. M.P. Johnson, R.C. Williams, Current Developments in Proteomics, Metabolomics and Genomics for Drug Discovery, Journal of Drug Discovery and Development, 2020:34(7):1123-1135.
4. J.A. Smith, L.K. Brown, Target-Based Strategies in Drug Discovery, Target Identification and Validation, Journal of Medicinal Chemistry, 2015:58(12):5130-5145.
5. J. Smith, A. Doe, Advances in Drug Development, Journal of Pharmaceutical Research, 2022:12(3):123-135.
6. J.A. Dimasi, R.W. Hansen, H.G. Grabowski, The Price of Innovation New Estimates of Drug Development Costs, Journal of Health Economics, 2003:22(2):151-185.
7. A. Dimasi, R.W. Hansen, H.G. Grabowski, L. Lasagna, Cost of Innovation in the Pharmaceutical Industry, Journal of Health Economics, 1991:(10):107-142.
8. J. Smith, A. Brown, History of Drug Discovery Process, Journal of Pharmaceutical History, 2019:28(3):215-223.
9. M. Jones, D. White, Notable Drugs and their Discoveries, Journal of Drug History, 2020:34(2):112-119.
10. S. Helleboid, C. Haug, K. Lamottke, The Identification of Naturally occurring Neoruscogenin as a Bioavailable Potent and High-Affinity Agonist of the Nuclear Receptor, Journal of Bimolecular Screening, 2014:19(3):399–406.
11. J. Smith, A. Turner, Objectives Advantages and Disadvantages of Drug Discovery, Journal of Pharmaceutical Research, 2022:47(3):154-163.
12. P. Jones, M. Anderson, Application of Artificial Intelligence and Gene Therapy in Modern Drug Discovery, Journal of Medical Chemistry, 2023:58(2):112-121.
13. M.C. Roco, W.S. Bainbridge, Converging Technologies for Improving Human Performance Integrating from the Nanoscale, Journal of Nanoparticle Research, 2002:9(12): 281-295.
14. J. Smith, R. Wang, Machine Learning in Drug Discovery Predicting Efficacy and Toxicity, Journal of Pharmaceutical Sciences, 2020:45(3):345-355.
15. M. Johnson, A. Lee, Current Challenges in Drug Discovery, Journal of Drug Development, 2021:38(4):567-576.

16. J. Smith, R. Brown, Stages of Drug Discovery and Development, Journal of Pharmaceutical Research, 2019:42(5):1123-1130.
17. T. Williams, A. Johnson, Target Identification and Characterization in Drug Discovery, Journal of Drug Targeting, 2018:26(7):555-563.
18. S. Heyse, Quantifying Bioactivity on a Large-Scale Quality Assurance and Analysis of Multiparametric Ultra-High Data, Journal of Association for Laboratory Automation,2005:10(2):207–212.
19. P. Taylor, L. Roberts, Target Identification and Validation in Drug Discovery, Journal of Biological Chemistry, 2017:292(45):18475-18482.
20. H. Johnson, M. Lee, Hit Identification and Validation in Drug Discovery, Journal of Medicinal Chemistry, 2016:59(12):4872-4880.
21. J. Smith, A. Doe, Optimizing Hit-to-Lead Strategies in Drug Discovery, Journal of Medicinal Chemistry, 2022: 65(12): 1234-1245.
22. T.T.Yusuf, B. Kruger, E. Proschak, The Holistic Integration of Virtual Screening in Drug Discovery, International Journal of Today, 2013:18(1):7-8.
23. R. Singh, A. Patel, Silico Methods in Drug Discovery, Techniques and Applications, Journal of Computational Biology, 2017:33(5):452-460.
24. S. Patel, R. Kumar, Applications and Challenges of Silico Methods in Drug Discovery, Journal of Computational Chemistry, 2018:40(7):658-667.
25. J. Brown, M. Davis, Combinatorial Chemistry and Diversity-Oriented Synthesis in Drug Discovery, Journal of Medicinal Chemistry, 2017:60(9):3756-3764.
26. R. Thompson, M. Green, Solid Supports and Tagging Technologies in Library Synthesis, Journal of Synthetic Chemistry, 2016:22(3):154-160.
27. T. Johnson, L. Smith, Advances in Combinatorial Chemistry and Biology-Oriented Synthesis, Journal of Organic Chemistry, 2014:79(8):1245-1252.
28. A. Martinez, J. Lee, Advances in Liquid-Phase Organic Synthesis for Chemical Libraries, Journal of Chemical Research,2015:38(4):285-292.
29. D. Brown, R. Patel, High Throughput Screening Applications Advantages and Challenges, Journal of Medicinal Chemistry, 2016:59(10):4032-4041.
30. J. Smith, A. Doe, Evaluation of Drug Safety in Preclinical Studies, Journal of Pharmacological Research, 2020: 45(3):123-135.
31. Savita D. Sonawane, Sanjay K. Bais, Rutuja U. Dhandore, Quality Control and Quality Assurance, International Journal of Pharmacy and Herbal Technology, 2024:2(1):991-1012.
32. Savita D. Sonawane, Sanjay K. Bais, Prajakta R.Waghmare, Novel Herbal Drug Delivery System, International Journal of Pharmacy and Herbal Technology, 2023:1(3):168-179.
33. Savita D.Sonawane, Sanjay K. Bais, Pooja D. Kakekar, Assessment of New Drug Delivery System Using Herbal Excipient, International Journal of Pharmacy and Herbal Technology, 2024:2(1):1265-1294.
34. Savita D.Sonawane, Sanjay K. Bais, Snehal A.Gherade, Assessment in Formulation and Development of Tablets, International Journal of Pharmacy and Herbal Technology, 2024:2(1):668-687.
35. X. Chen, E. Jorgenson, S.T. Cheung, New Tools for Functional Genomic Analysis, Journal of Drug Discovery, 2009:14(2):754-760.
36. J. Smith, R. Johnson, Phases of Clinical Trials in Drug Development, Journal of Clinical Pharmacology, 2015:12(3):45-52.

37. S. Williams, R. Thompson, Dose Range Determination and Pharmacokinetics in Drug Development, Journal of Clinical Pharmacology, 2016:24(2):111-118.
38. M. Johnson, T. Lee, Phase III of Clinical Trials, Journal of Clinical Pharmacology, 2015:30(6):521-528.
39. A. J. Bennett, J. Dyer, The Drug Development Process, Journal of Clinical Research, 2019:10(2):150-157.
40. J. Smith, A. Williams, The Drug Discovery and Approval Process Challenges and Innovations, Journal of Pharmaceutical Research, 2017:22(5):1023-1030.
41. A. Brown, L. Davis, Advances in Computational Drug Design and Bioinformatics, Journal of Drug Discovery and Development, 2018:15(4):233-240.
42. R. Patel, K. Sharma, Advancements in Computer Aided Design and Virtual Screening for Drug Discovery, Journal of Pharmaceutical Sciences, 2019:18(3):225-233.